BiotechTubeBiotechTube
Home/Pipeline/NurOwn® (debamestrocel)

NurOwn® (debamestrocel)

Amyotrophic Lateral Sclerosis (ALS)

Phase 3bActive (SPA agreed)

Key Facts

Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 3b
Status
Active (SPA agreed)
Company
BrainStorm Cell Therapeutics

About BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics is dedicated to defeating neurodegenerative diseases through its innovative NurOwn® autologous cellular technology platform. The company's lead program targets ALS, with a Phase 3b trial underway under an FDA Special Protocol Assessment (SPA). BrainStorm leverages proprietary methods to engineer a patient's own mesenchymal stem cells to secrete high levels of neurotrophic factors, aiming to slow disease progression.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

DrugCompanyPhase
Utreloxastat (PTC857)PTC TherapeuticsPhase 2
SAR443820/DNL788Denali TherapeuticsPhase 2
PegcetacoplanApellis PharmaceuticalsPhase 2
RELYVRIO/ALBRIOZA (AMX0035)Amylyx PharmaceuticalsApproved/Commercial
AMX0035Amylyx PharmaceuticalsPhase 3
AMX0114Amylyx PharmaceuticalsPhase 1
Taldefgrobep alfaBiohavenPhase 2/3
AMT-162uniQurePreclinical
AAV-UPF1MeiraGTxPreclinical
TegoprubartEledon PharmaceuticalsPhase 2
Intranasal ForalumabTiziana Life SciencesPhase 2
TDP-43 ProgramKorro BioDiscovery